Literature DB >> 32866943

Renal cell carcinoma: The role of radical surgery on different patterns of local or distant recurrence.

Gregorio Di Franco1, Matteo Palmeri1, Andrea Sbrana2, Desirée Gianardi1, Niccolò Furbetta1, Simone Guadagni1, Matteo Bianchini1, Gianni Stefanini1, Giulia Adamo1, Luca Emanuele Pollina3, Luca Galli2, Giulio Di Candio1, Luca Morelli4.   

Abstract

INTRODUCTION: With the increasing reliance on targeted therapies and immunotherapy, no standard management strategy is today available for the treatment of locally, distant, or both renal cell carcinoma (RCC) recurrences, and their surgical treatment seems to play a crucial role. We report the 20-year experience of our center evaluating the short- and long-term outcomes of patients undergone surgical resection of RCC recurrences, and the possible role of repeated surgical resections of RCC recurrences.
MATERIALS AND METHODS: From January 1999 to January 2019, 40 patients underwent surgical resection of isolated locally recurrent RCC (iLR-RCC-group), locally recurrent RCC associated with the presence of distant recurrence (LR-DR-RCC-group), and distant-only recurrent RCC (DR-RCC-group). Data regarding pre-, intra-, post-operative course, and follow-up, prospectively collected in an institutional database, were retrospectively analyzed and compared.
RESULTS: iLR-RCC-group was composed of 9 patients, LR-DR-RCC-group of 6 patients, and DR-RCC-group of 25 patients. The recurrence rate was 55.6% (5/9 patients) in iLR-RCC-group, 50% (3/6 patients) in LR-DR-RCC-group, and 44% (11/25) patients in DR-RCC-group, p = 0.830. 3/5 (60%) patients in iLR-RCC-group, 2/3 (66.7%) patients in LR-DR-RCC-group, and 7/11 (63.6%) patients in DR-RCC group underwent to almost one further local treatments of their recurrences, respectively (p = 0.981). No differences in the mean disease-free survival (p = 0.384), overall survival (OS) (p = 0.881), and cancer-specific survival (p = 0.265) were reported between the three groups. In DR-RCC-group, patients who underwent further local treatments of new recurrences presented a longer OS: 150.7 versus 66.5 months (p = 0.004).
CONCLUSIONS: A surgical resection of RCC recurrences should be always taken in consideration, also in metastatic patients and/or in those who have already undergone surgery of previous RCC recurrence, whenever radicality is still possible, because this approach may offer a potentially long survival.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Distant RCC recurrence; Local RCC recurrence; RCC recurrence

Year:  2020        PMID: 32866943     DOI: 10.1016/j.suronc.2020.08.002

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  4 in total

1.  HIF-1α Induces HECTD2 Up-Regulation and Aggravates the Malignant Progression of Renal Cell Cancer via Repressing miR-320a.

Authors:  Dong Lv; Taimin Shen; Juncheng Yao; Qi Yang; Ying Xiang; Zhiwei Ma
Journal:  Front Cell Dev Biol       Date:  2021-12-24

2.  Transplant or dialysis: What's the better choice for RCC-induced ESRD patients? A 20-year analysis of OPTN/UNOS data.

Authors:  Xiaowei Hao; Wenhui Lai; Xinze Xia; Junnan Xu; Yangyang Wu; Chao Lv; Kaikai Lv; Shuai Huang; Zhenjun Luo; Qingyang Meng; Qing Yuan; Jun Dong
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

3.  MiR-6838-5p facilitates the proliferation and invasion of renal cell carcinoma cells through inhibiting the DMTF1/ARF-p53 axis.

Authors:  Xiaoqiang Zhai; Yan Wu; Dong Zhang; Hecheng Li; Tie Chong; Jun Zhao
Journal:  J Bioenerg Biomembr       Date:  2021-03-08       Impact factor: 2.945

Review 4.  Perioperative Nutritional Aspects in Total Pancreatectomy: A Comprehensive Review of the Literature.

Authors:  Niccolò Furbetta; Annalisa Comandatore; Desirée Gianardi; Matteo Palmeri; Gregorio Di Franco; Simone Guadagni; Giovanni Caprili; Matteo Bianchini; Lorenzo Maria Fatucchi; Martina Picchi; Luca Bastiani; Giandomenico Biancofiore; Giulio Di Candio; Luca Morelli
Journal:  Nutrients       Date:  2021-05-22       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.